Wellcovorin
(Leucovorin)ApprovedSmall molecule
Leucovorin is used to reduce the toxic side effects of certain cancer medications, particularly methotrexate, and to enhance the effectiveness of some cancer treatments. It's also used to treat a type of anemia caused by folate deficiency.[2] Wellcovorin is currently approved and in use across 65 indications[4].[1]
Wellcovorin is one of 1044 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Approved.
65
Indications
395
Total Trials
40
Active Trials
1,043
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 65 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Wellcovorin
GGlaxo Dba Glaxosmithkline
Approved
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer33 trials
Show 30 more trials
Pancreatic Cancer21 trials
FOLFIRINOX + NIS793 in Pancreatic Cancer
Terminated·—·Phase 1·NCT05417386·4 enrolled
Show 18 more trials
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Unknown status·—·Phase 1·NCT03703063·30 enrolled
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1/2·NCT06259058·96 enrolled
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Terminated·—·Phase 2·NCT05546411·8 enrolled
Colorectal Cancer18 trials
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2/3·NCT02415699·100 enrolled
Show 15 more trials
Botensilimab and Balstilimab Optimization in Colorectal Cancer
Active, not recruiting·—·Phase 2·NCT06268015·16 enrolled
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Completed·—·Phase 1/2·NCT01206530·50 enrolled
Gastric Cancer10 trials
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Completed·—·Phase 2·NCT01747551·64 enrolled
Show 7 more trials
Acute Lymphoblastic Leukemia7 trials
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled
Show 4 more trials
70 more indications
Pancreatic Adenocarcinoma5 trials
Breast Cancer5 trials
Show 2 more trials
Locally-advanced Rectal Cancer4 trials
Treatment4 trials
FOLFIRINOX for 2nd-line Treatment of BTC
Completed·—·Phase 2·NCT03778593·34 enrolled
Adenocarcinoma4 trials
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
Unknown status·—·Phase 2/3·NCT04393584·538 enrolled
Show 1 more trial
Advanced Solid Tumors3 trials
Lymphoma3 trials
Radiation Therapy3 trials
Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery
Completed·—·Phase 2·NCT01263171·60 enrolled
Intestinal Cancer3 trials
Squamous Cell Carcinoma3 trials
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Completed·—·Phase 2·NCT00139230·30 enrolled
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
Completed·—·Phase 1/2·NCT00139243·30 enrolled
Hepatocellular Carcinoma3 trials
Methotrexate3 trials
Colon Cancer2 trials
Pancreatic Ductal Adenocarcinoma2 trials
Gastroesophageal Junction Cancer2 trials
Patients With Locally Advanced Rectal Cancer2 trials
Chemotherapy2 trials
Leukemia2 trials
Prognosis2 trials
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099188·27 enrolled
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099175·41 enrolled
Central Nervous System Lymphoma2 trials
Rectal Cancer2 trials
Gastroesophageal Junction Adenocarcinoma2 trials
Neoadjuvant Therapy1 trial
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06684158·70 enrolled
Metastatic Colon Cancer1 trial
Pancreas Cancer1 trial
mCRC1 trial
Escalated Dose of Irinotecan in mCRC
Completed·—·N/A·NCT02256800·213 enrolled
Advanced Cancer1 trial
Clinical Trial1 trial
Hypofractionated Radiotherapy1 trial
Hematologic Malignancies1 trial
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Recruiting·—·Phase 1·NCT05292664·30 enrolled
Gastroesophageal Junction1 trial
Glioblastoma Multiforme1 trial
Merkel Cell Carcinoma1 trial
Esophageal Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Non-Small Cell Lung Cancer1 trial
Metastasis1 trial
ESS1 trial
Induction Chemotherapy1 trial
Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer
Completed·—·Phase 2·NCT01467115·1 enrolled
Efficacy1 trial
Advanced Solid Malignancies1 trial
Esophageal Adenocarcinoma1 trial
Unresectable1 trial
Mantle Cell Lymphoma1 trial
Biliary Cancer1 trial
Sandhoff disease1 trial
Ovarian Cancer1 trial
Safety and Efficacy1 trial
Lenalidomide1 trial
Locally Advanced or Metastatic Solid Tumors1 trial
Patients With Solid Tumors1 trial
Metastatic Solid Tumors1 trial
Neoadjuvant Treatment1 trial
Oxaliplatin1 trial
Neoadjuvant1 trial
Osteosarcoma1 trial
Biliary Tract Cancer1 trial
Stomach Cancer1 trial
Urothelial Cancer1 trial
Esophageal Squamous Cell Carcinoma1 trial
Gastric Adenocarcinoma1 trial
Stage III Colon Cancer1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jul 8, 1983
WELLCOVORIN
NDA NDA018342
Jan 30, 1986
LEUCOVORIN CALCIUM
NDA NDA018459
Jan 30, 1987
LEUCOVORIN CALCIUM
NDA NDA008107
Feb 3, 2026
VYKOURA
NDA NDA220406
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Wellcovorin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Leucovorin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline
Patent Landscape[6]
Patent Cliff
Dec 23, 2044
Earliest patent expiration — generic entry possible after this date
Patent #Expires
12564592Dec 23, 2044